Worldwide Racial and Ethnic Distribution of α1-Antitrypsin Deficiency: Summary of an Analysis of Published Genetic Epidemiologic Surveys

Study objectives α 1 -antitrypsin (AAT) deficiency is a genetic disease that is widely known in Europe as a disease of white individuals, who, along with their descendants in other parts of the world, are at the highest risk for liver and/or lung disease. There is a limited database of individuals affected by this disease worldwide. It has been estimated, for example, that there are 70,000 to 100,00 individuals affected in the United States, with comparable numbers in Europe. Study design Genetic epidemiologic studies in the peer-reviewed literature have been used in an exploratory study to estimate the number of carriers and the number of those individuals who are homozygous or heterozygous for the two most common defective alleles for AAT deficiency in 58 individual countries. The total country database of 373 control cohorts has been combined to estimate the numbers of carriers and deficiency allele combinations for PiS and PiZ in 11 geographic regions and worldwide. The study was designed to be illustrative rather than comprehensive, and more detailed publication of the enormous database developed in this exploratory study is planned. Conclusions The database presented indicates that in a total population of 4.4 billion in the countries surveyed worldwide, there are at least 116 million carriers (PiMS and PiMZ) and 3.4 million deficiency allele combinations (PiSS, PiSZ, and PiZZ). Furthermore, this database demonstrates that AAT deficiency is found in various populations of African blacks, Arabs and Jews in the Middle East, whites in Australia/New Zealand, Europe, and North America, central Asians, far east Asians, and southeast Asians. These data demonstrate that AAT deficiency is not just a disease of whites in Europe, but that it affects individuals in all racial subgroups worldwide. In addition, AAT deficiency may be one of the most common serious hereditary disorders in the world.

[1]  W. Endres,et al.  Inherited metabolic diseases affecting the carrier , 1997, Journal of Inherited Metabolic Disease.

[2]  I. Blanco,et al.  Genetic epidemiology of alpha‐1 antitrypsin deficiency in southern Europe: France, Italy, Portugal and Spain , 2003, Clinical Genetics.

[3]  R. Giugliani,et al.  Molecular analysis of the Pi*Z allele in patients with liver disease. , 2001, American journal of medical genetics.

[4]  I. Blanco,et al.  Distribution of α1‐antitrypsin PI S and PI Z frequencies in countries outside Europe: a meta‐analysis , 2001, Clinical genetics.

[5]  I. Blanco,et al.  Alpha‐1‐antitrypsin PI phenotypes S and Z in Europe: an analysis of the published surveys , 2001, Clinical genetics.

[6]  Spitsyn Va,et al.  Genetic predisposition to development of toxic liver cirrhosis caused by alcohol , 2001 .

[7]  I. Blanco,et al.  Alpha1-antitrypsin Pi phenotypes S and Z in Spain: an analysis of the published surveys. , 2001, Respiratory medicine.

[8]  A. Amorim,et al.  Patterns of haplotype diversity within the serpin gene cluster at 14q32.1: insights into the natural history of the α1-antitrypsin polymorphism , 2000, Human Genetics.

[9]  T. Therneau,et al.  Increased risk of chronic liver failure in adults with heterozygous α‐antitrypsin deficiency , 1998 .

[10]  D. Lomas,et al.  Alpha1-antitrypsin deficiency, cirrhosis and emphysema , 1998 .

[11]  D. Hutchison.  Alpha 1-antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. , 1998, Respiratory medicine.

[12]  J. Katzmann,et al.  Alpha-1-Antitrypsin Deficiency in Spontaneous Intracranial Arterial Dissections , 1998, Cerebrovascular Diseases.

[13]  M. Schluchter,et al.  Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group. , 1996, American journal of respiratory and critical care medicine.

[14]  M. González-Coira,et al.  PI locus (alpha-1-antitrypsin) allelic frequencies in an Andean Venezuelan population. , 1996, Gene geography : a computerized bulletin on human gene frequencies.

[15]  J. Haywood.  The Penguin Historical Atlas of the Vikings , 1995 .

[16]  Y. Lolin,et al.  Alpha‐ 1‐antitrypsin phenotypes and associated disease patterns in neurological patients , 1995, Acta neurologica Scandinavica.

[17]  D. Cox,et al.  Physical and genetic mapping of the serpin gene cluster at 14q32.1: allelic association and a unique haplotype associated with alpha 1-antitrypsin deficiency. , 1994, American journal of human genetics.

[18]  K. Pittschieler.  Heterozygotes and liver involvement , 1994, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[19]  M. Brantly,et al.  Clinical features and molecular characteristics of alpha 1-antitrypsin deficiency. , 1994, Annals of allergy.

[20]  P. Moral,et al.  Serum protein markers in the Piaroa Indians of Amazonia (Venezuela). , 1993, Human heredity.

[21]  J. Pappas,et al.  Variants of α1-Antitrypsin in Puerto Rican Children With Asthma , 1993 .

[22]  K. Pittschieler.  Liver Disease and Heterozygous Alpha‐1‐Antitrypsin Deficiency , 1991, Acta paediatrica Scandinavica.

[23]  F. Salzano,et al.  Electrophoretic and isoelectric focusing studies in Brazilian Indians: data on four systems. , 1989, Human biology.

[24]  R. Feld,et al.  Heterozygosity of α1-Antitrypsin: A Health Risk? , 1989 .

[25]  D. States,et al.  The alpha 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. , 1989, Chest.

[26]  G. Gourley,et al.  α1‐Antitrypsin Deficiency and the PiMS Phenotype , 1989, Journal of Pediatric Gastroenterology and Nutrition.

[27]  R. Crystal,et al.  Molecular basis of alpha-1-antitrypsin deficiency. , 1988, The American journal of medicine.

[28]  J. Pierce.  Antitrypsin and emphysema. Perspective and prospects. , 1988, JAMA.

[29]  S. Nevo.  Protease inhibitor subtypes in some population groups from Israel. , 1987, Human heredity.

[30]  A. Sastre,et al.  Alpha 1-antitrypsin Pi-types in 965 COPD patients. , 1986, Chest.

[31]  J. Carlson,et al.  Chronic 'cryptogenic' liver disease and malignant hepatoma in intermediate alpha 1-antitrypsin deficiency identified by a Pi Z-specific monoclonal antibody. , 1985, Scandinavian journal of gastroenterology.

[32]  D. Cox,et al.  DNA restriction fragments associated with α1-antitrypsin indicate a single origin for deficiency allele PI Z , 1985, Nature.

[33]  C. Mittman.  The PiMZ phenotype: is it a significant risk factor for the development of chronic obstructive lung disease? , 2015, The American review of respiratory disease.

[34]  F. Muñoz-López,et al.  Cirrhosis and heterozygous alpha1-antitrypsin deficiency in a 4-year-old girl. , 1976, Helvetica paediatrica acta.

[35]  J. Lieberman,et al.  Hepatocellular carcinoma and intermediate alpha1-antitrypsin deficiency (MZ phenotype). , 1975, American journal of clinical pathology.

[36]  J. Martin,et al.  Le système Pi dans les populations normande et amérindienne , 1972 .

[37]  R. K. Larson,et al.  Obstructive Lung Disease and α1-Antitrypsin Deficiency Gene Heterozygosity , 1969, Science.

[38]  J. Lieberman.  Heterozygous and homozygous alpha1-antitrypsin deficiency in patients with pulmonary emphysema. , 1969, The New England journal of medicine.